MA41759A - Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide - Google Patents

Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide

Info

Publication number
MA41759A
MA41759A MA041759A MA41759A MA41759A MA 41759 A MA41759 A MA 41759A MA 041759 A MA041759 A MA 041759A MA 41759 A MA41759 A MA 41759A MA 41759 A MA41759 A MA 41759A
Authority
MA
Morocco
Prior art keywords
glucosidase
inclusion
exon
antisens
induced
Prior art date
Application number
MA041759A
Other languages
English (en)
Inventor
Richard Keith Bestwick
Sue Fletcher
Gunnar James Hanson
Frederick J Schnell
Stephen Donald Wilton
Original Assignee
Univ Murdoch
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Murdoch, Sarepta Therapeutics Inc filed Critical Univ Murdoch
Publication of MA41759A publication Critical patent/MA41759A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Abstract

La présente invention concerne des oligomères antisens et des compositions apparentées et des procédés d'induction d'inclusion d'exon en tant que traitement pour la maladie de stockage du glycogène de type ii (gsd-ii) (également appelée maladie de pompe, glycogénose ii, déficit en acide maltase, déficience en glucosidase, et déficience en alpha-glucosidase lysosomale), et plus spécifiquement concerne l'induction de l'inclusion de l'exon 2 et ainsi la restauration des niveaux de la protéine alpha-glucosidase acide (gaa) enzymatiquement active codée par le gène gaa.
MA041759A 2015-02-27 2016-02-29 Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide MA41759A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126346P 2015-02-27 2015-02-27
US201562234263P 2015-09-29 2015-09-29
US201662300635P 2016-02-26 2016-02-26

Publications (1)

Publication Number Publication Date
MA41759A true MA41759A (fr) 2018-01-03

Family

ID=56789314

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041759A MA41759A (fr) 2015-02-27 2016-02-29 Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide

Country Status (12)

Country Link
US (1) US20180216111A1 (fr)
EP (1) EP3262056A4 (fr)
JP (3) JP2018509143A (fr)
AU (2) AU2016224976A1 (fr)
BR (1) BR112017018383B1 (fr)
CA (1) CA2977528A1 (fr)
HK (1) HK1249106A1 (fr)
IL (2) IL254112B (fr)
MA (1) MA41759A (fr)
MX (1) MX2017011004A (fr)
TW (2) TW201702378A (fr)
WO (1) WO2016138534A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041935A1 (fr) 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Inclusion de l'exon 2 induite par antisens dans une alpha-glucosidase acide
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
KR102620328B1 (ko) 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강
KR20240035901A (ko) 2015-05-19 2024-03-18 사렙타 쎄러퓨틱스 인코퍼레이티드 펩티드 올리고뉴클레오티드 콘주게이트
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
WO2017106377A1 (fr) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Oligomères antisens destinés au traitement du retard mental dominant autosomique 5 et du syndrome de dravet
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
JP2018538302A (ja) 2015-12-15 2018-12-27 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチド複合体
JP7033547B2 (ja) 2016-04-18 2022-03-10 サレプタ セラピューティクス， インコーポレイテッド 酸性アルファ－グルコシダーゼ遺伝子に関連する疾患を処置するためのアンチセンスオリゴマーおよびそれを用いる方法
NL2017295B1 (en) * 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
NL2017294B1 (en) * 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
SG10202108375XA (en) 2017-08-25 2021-09-29 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
JP2021521794A (ja) * 2018-04-26 2021-08-30 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
US20230287410A1 (en) 2020-05-11 2023-09-14 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023283629A1 (fr) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs formulations pour traiter la dystrophie musculaire facio-scapulo-humérale
WO2023055774A1 (fr) * 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Oligonucléotides antisens ayant une ou plusieurs unités abasiques
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024016003A2 (fr) 2022-07-14 2024-01-18 The Broad Institute, Inc. Capsides d'aav qui permettent une distribution de gènes à l'échelle du snc par l'intermédiaire d'interactions avec le récepteur de transferrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005020745D1 (de) * 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2799501C (fr) * 2010-05-28 2022-02-15 Sarepta Therapeutics, Inc. Analogues oligonucleotidiques ayant des liaisons modifiees entre sous-unites et/ou des groupes terminaux modifies
KR102183273B1 (ko) * 2011-05-05 2020-11-27 사렙타 쎄러퓨틱스, 인코퍼레이티드 펩타이드 올리고뉴클레오타이드 접합체
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EA035030B1 (ru) * 2011-11-18 2020-04-20 Сарепта Терапьютикс, Инк. Модифицированные морфолиновые аналоги олигонуклеотидов
BR122020016865B1 (pt) * 2013-03-14 2022-12-27 Sarepta Therapeutics, Inc. Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
EP3041935A1 (fr) * 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Inclusion de l'exon 2 induite par antisens dans une alpha-glucosidase acide
EP3143141B1 (fr) * 2014-05-16 2019-10-02 Oregon State University Composés antisens antibactériens et procédés associés
US10308940B2 (en) * 2014-06-10 2019-06-04 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of Pompe disease

Also Published As

Publication number Publication date
IL281199A (en) 2021-04-29
MX2017011004A (es) 2018-02-09
TW202403045A (zh) 2024-01-16
JP2023129494A (ja) 2023-09-14
AU2016224976A1 (en) 2017-09-14
IL254112A (en) 2018-06-28
EP3262056A2 (fr) 2018-01-03
AU2020203825B2 (en) 2021-08-05
TW201702378A (zh) 2017-01-16
AU2020203825A1 (en) 2020-07-02
BR112017018383B1 (pt) 2023-04-25
US20180216111A1 (en) 2018-08-02
HK1249106A1 (zh) 2018-10-26
JP2018509143A (ja) 2018-04-05
IL254112B (en) 2021-04-29
CA2977528A1 (fr) 2016-09-01
JP2021166543A (ja) 2021-10-21
IL281199B (en) 2022-05-01
EP3262056A4 (fr) 2018-09-19
WO2016138534A3 (fr) 2016-12-22
BR112017018383A2 (pt) 2018-09-04
WO2016138534A2 (fr) 2016-09-01

Similar Documents

Publication Publication Date Title
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
MX2016002934A (es) Inclusion del exon 2 inducida por antisentido en la alfa-glucosidasa ácida.
ES2542350T3 (es) Composición detergente para lavavajillas
EA201001393A1 (ru) Липазы с высокой специфичностью к жирным кислотам с короткой цепью и их использование
EA201792663A1 (ru) Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
EP2493507A4 (fr) Antagonistes et variants ax213 et ax132 pcsk9
EA202191313A1 (ru) Композиции на основе липидных наночастиц
MA35125B1 (fr) Alpha glucosidase acide modifiee a traitement accelere
CO6700848A2 (es) Formulaciones recubiertas entéricas de pancrelipilasa, de baja intensidad
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
ATE516353T1 (de) Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
MY162056A (en) Diagnosis and treatment of cancer using anti -ereg antibody
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
MA50258A1 (fr) Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
EA201100907A1 (ru) Композиции и способы ингибирования экспрессии гена pcsk9
EA200702642A1 (ru) Новый способ для ферментативного снижения содержания акриламида в пищевых продуктах
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
IN2012DN00801A (fr)
MA44593A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
SI2751279T1 (en) Procedures and compositions for detecting the level of activity of lysosomal exocytosis and application procedures
EA200971059A1 (ru) Лечение и профилактика гриппа
EA201590611A1 (ru) Новые молекулы, связывающие il-17a, и их медицинское применение